Compare HUBS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBS | UTHR |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 25.1B |
| IPO Year | 2014 | 1999 |
| Metric | HUBS | UTHR |
|---|---|---|
| Price | $240.72 | $571.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 32 | 14 |
| Target Price | $435.19 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 1.4M | 387.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 855.56 | 13.07 |
| EPS | 0.86 | ★ 27.86 |
| Revenue | $375,612,000.00 | ★ $1,483,300,000.00 |
| Revenue This Year | $20.46 | $6.39 |
| Revenue Next Year | $16.01 | $14.18 |
| P/E Ratio | $256.36 | ★ $20.56 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $187.45 | $272.18 |
| 52 Week High | $670.54 | $607.89 |
| Indicator | HUBS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 55.41 |
| Support Level | $209.40 | $560.16 |
| Resistance Level | $250.14 | $593.65 |
| Average True Range (ATR) | 12.02 | 12.17 |
| MACD | 3.02 | -2.95 |
| Stochastic Oscillator | 83.96 | 33.53 |
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.